Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course versus long-course pre-operative mFOLFIRINOX or PAXG in resectable pancreatic ductal adenocarcinoma
2020-003080-26Phase 2Active
- Sponsor
- Fondazione GISCAD
- Start
- Aug 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of mFOLFIRINOX and PAXG in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Fondazione GISCAD. Primary endpoint: 1-year event-free survival (EFS). Started Aug 2021; status: active.
02
Drugs
mFOLFIRINOXPAXG
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2020-003080-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003080-26.